Mr. Barberich has been a director of HeartWare since April 2008. He is the Founder and former President, Chief Executive Officer and Chairman of Sepracor Inc., a publicly traded pharmaceutical company based in Marlborough, Massachusetts which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009.
He founded Sepracor in 1984 and was President and Chief Executive Officer through 1999 when he also became chairman. He serves on the boards of BioSphere Medical, Gemin X Biotechnologies and Resolyx Pharmaceuticals. Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Millipore Corporation, a company that provides separations products to the life science research, pharmaceutical, biotechnology and electronic markets.
Mr. Barberich is a graduate of Kings College. He holds a Bachelors of Science Degree in Chemistry.
Mr. Cornell is a Partner and Managing Director at Goldner Hawn Johnson & Morrison, Inc. (GHJ&M), a middle-market private equity firm, which he joined in 2013. Prior to joining GHJ&M, Mr. Cornell worked at Medtronic, Inc. from 2003 to 2013. At Medtronic, Mr. Cornell supported the transaction activity of various Medtronic businesses and initiatives, and he led the corporate development group during his last five years at the company. As Vice President of Corporate Development, he was responsible for global acquisition, divestiture, venture investment and strategic transaction activity. Earlier in his tenure with Medtronic, Mr. Cornell led transaction activity related to interventional cardiology and cardiac surgery, as well as musculoskeletal and international business development. Prior to joining Medtronic, Mr. Cornell was a corporate lawyer at Sidley Austin, LLP in Chicago, concentrating on mergers and acquisitions and securities offerings.
Mr. Cornell earned a bachelor's degree in accounting from Marquette University and holds a Juris Doctorate from the University of Pennsylvania Law School. He is a Chartered Financial Analyst and Certified Public Accountant.
Ms. Feldmann has been a director for HeartWare since March 2012. Ms. Feldmann is a retired certified public accountant with 27 years of experience in two large global accounting firms, and currently serves on several public company and not-for-profit boards.
Previously, Ms. Feldmann served as the Life Sciences Business Development Officer for the Boston law firm of Palmer & Dodge, LLP. From 1994 to 2002, Ms. Feldmann was a partner with KPMG LLP, primarily serving as Partner-in-Charge of its National Medical Technology Practice. From 1975 to 1994, Ms. Feldmann was employed by Coopers & Lybrand (now PricewaterhouseCoopers LLP), and during that time was named Partner-in-Charge of its Life Sciences Practice. Ms. Feldmann is a director of Steris Corporation, Hanger Orthopedic Group, Inc. and Atrius Health. She previously served on the Board of Hayes Lemmerz International, Inc.
Ms. Feldmann earned a Bachelor of Science degree in Accounting from Boston College and holds a Professional Director Certification from the American College of Corporate Directors.
Managing Director, Chief Executive Officer
Mr. Godshall has been the Chief Executive Officer of HeartWare since September 2006. He became a director of HeartWare in October 2006.
Prior to joining HeartWare, Mr. Godshall served in various executive and managerial positions at Boston Scientific Corporation, where he had been employed since 1990, including as a member of Boston Scientific’s Operating Committee, and since January 2005 as President, Vascular Surgery. Prior to that, Mr. Godshall spent five years as Vice President, Business Development, where he was focused on acquisition strategies for the cardiology, electrophysiology, neuroradiology and vascular surgery divisions.
Mr. Godshall has a Bachelor of Arts degree in Business from Lafayette College and Masters of Business Administration from Northeastern University.
Seth Harrison M.D.
Non-Executive Director, Deputy Chairman
Dr. Harrison has been a director and deputy chairman and non-executive director of HeartWare since November 2004 and was Chief Executive Officer of HeartWare from July 2003 through November 2004.
Since September 1999, Dr. Harrison has been Managing General Partner of Apple Tree Partners I, L.P., an early stage life sciences venture capital firm, which is our major shareholder. Prior to September 1999, he held senior executive positions with Oak Investment Partners, Sevin Rosen Funds and Nazem & Company. Dr. Harrison received a Bachelor of Arts from Princeton University. He received his medical degree and a Masters of Business Administration from Columbia University and completed a surgery internship at Columbia Presbyterian Hospital in New York City.
He serves on the board of and chairs the Finance Committee of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation-sponsored public-private partnership engaged in the development of anti-HIV microbicides.
Ray Larkin, Jr.
Non-Executive Director, Chairman
Mr. Larkin has been a director of HeartWare since October 2008. He is chairman of Align Technology, Inc. (Nasdaq: ALGN) and Novasys Medical, Inc. Align Technology is engaged in the design, manufacture and marketing of novel orthodontic products. Novasys Medical is a privately held company focused on the development of innovative therapies in women’s health.
He is also a director of Neuropace, a privately held company developing implantable devices for treating neurological disorders, and TherOx, a company focused on treating oxygen-deprived tissue in heart-attack victims. He is also a Venture Partner at Cutlass Capital, a healthcare venture capital firm, and an Executive Committee Member at Synecor, an incubator of innovative early stage medical technologies. Mr. Larkin spent some 15 years with critical care device company, Nellcor, which he joined in 1983 as Vice President Sales and Marketing. He was appointed President and Chief Executive Officer of Nellcor in 1989.
Larkin subsequently served as Chairman and Chief Executive Officer of Eunoe, Inc., a company focused on neurological disorders, until it was acquired by Integra LifeSciences Holdings Corporation in 2005. Mr. Larkin is a graduate of LaSalle University and a former Captain in the United States Marine Corps.
Stephen Oesterle, MD
Dr. Oesterle has been a director of HeartWare since January 2016. He is a Venture Partner at the global venture capital firm New Enterprise Associates, Inc. (“NEA”), where he focuses on NEA’s medical device investing practice, and he acts as a strategic advisor to investment firms EQT and Temasek Holdings. Prior to joining NEA in 2015, Dr. Oesterle served as Medtronic, Inc.’s Senior Vice President for Medicine and Technology and as a member of the Executive Committee where he provided executive leadership for Medtronic scientific research, technological strategies and development of relationships with medical communities, technical universities, financial institutions and emerging medical device companies around the world. Prior to joining Medtronic in 2002, Dr. Oesterle served as Associate Professor of Medicine at the Harvard University Medical School and Director of Invasive Cardiology Services at Massachusetts General Hospital, Boston. Dr. Oesterle developed and directed interventional cardiology programs at Good Samaritan Hospital, Los Angeles from 1986 to 1991, at Georgetown University from 1991 to 1992, and at Stanford University from 1992 to 1998.
Dr. Oesterle graduated summa cum laude from Harvard in 1973 and went on to receive his M.D. from Yale University School of Medicine in 1977. He was a post-doctoral fellow in cardiology at Stanford University, where he subsequently served on the faculty for more than a decade.
Mr. Stockman has been a director of HeartWare since December 2006. Mr. Stockman became the President and Chief Executive Officer of Group Outcome LLC in 1999. Group Outcome is a U.S.-based merchant banking firm which deploys its capital and that of its financial partners in private equity and venture capital investments in medical technology companies.
He is also the co-founder and Chairman of REVA Medical, Inc., an interventional coronary medical device company. Prior to establishing Group Outcome LLC, Mr. Stockman spent eighteen years with Johnston Associates and Narragansett Capital Corporation, where he focused on venture capital investments in healthcare.
Mr. Stockman holds a Bachelor’s Degree from Harvard University and a Masters in Business Administration from The Tuck School at Dartmouth College.
Mr. Thomas has been a director and non-executive chairman of HeartWare since November 2004. He is currently a director of a number of Australian public companies, including Virgin Blue Holdings Limited and Tower Australia Limited.
Between October 2004 and September 2008, Mr. Thomas was a consultant to Citigroup Corporate and Investment Bank and was Chairman of Global Corporate and Investment Bank, Australia and New Zealand, of Citigroup Global Markets Australia Pty Limited between March 2003 and September 2004. Prior thereto, Mr. Thomas was CEO of Citigroup’s (formerly known as Salomon Smith Barney) Corporate and Investment Bank, Australia and New Zealand, from October 1999 until February 2003.
Mr. Thomas holds a Bachelor of Economics from Monash University, Australia. He is currently Chairman of the Stockbrokers Association of Australia and is a Master Stockbroker and has also been a member of the Financial Services Institute of Australasia for more than three decades and a Fellow for a decade. Mr. Thomas is a director of O’Connell Street Associates and Grahger Capital Securities, as well as a Fellow of the Australian Institute of Company Directors and President of the State Library Council of New South Wales.
Denis Wade, MD
Dr. Wade has been a director of HeartWare since December 2004. From 1998 until his retirement in 2003, Dr. Wade was Chairman and Managing Director of Johnson & Johnson Research Pty Ltd, a research arm of Johnson & Johnson. Prior to that position, he was the Foundation Professor of Clinical Pharmacology at the University of New South Wales in Australia.
Dr. Wade has served on a number of industry and government bodies in Australia. He is a former President of the Australian Society of Clinical and Experimental Pharmacology and has held senior positions in the International Union of Pharmacology, serving as Chairman of the Clinical Pharmacology Section.
Dr. Wade holds a Bachelor’s Degree in Medicine and Surgery from the University of New South Wales (Australia) and a Doctorate in Philosophy from Oxford (United Kingdom). He was awarded an Honorary Doctorate in Science from the University of New South Wales. He is a Fellow of the Royal Australasian College of Physicians and the Australian Academy of Technological Sciences and Engineering.